VAXCYTE, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 115.07 USD | -1.00% |
|
+5.56% | +83.47% |
| 10/09 | Analyst recommendations: Apple, Oracle, Progressive, Dollar Tree... |  |
| 10/09 | Mizuho Boosts Price Target on Vaxcyte to $163 From $113, Maintains Outperform Rating | MT |
Main competitors
| Revenues ($) (Y-1) | Net margin (Y-1) | Operating Margin (Y-1) | ROE (Y-1) | ROA (Y-1) | Leverage (Debt/EBITDA) (Y-1) | ||
|---|---|---|---|---|---|---|---|
| 1.31TCr | +30.14% | +39.08% | +20.74% | +16.20% | -1.6x | ||
| 986.92Cr | +36.68% | +44.33% | +22.99% | +17.71% | -2.46x | ||
| 129.08Cr | -23.26% | -33.51% | -8.54% | -7.69% | 10.14x | ||
| 421.01Cr | +24.36% | +18.08% | +4.62% | +4.02% | -13.1x | ||
| 245.88Cr | -35.86% | -49.12% | -22.26% | -14.47% | 2.05x | ||
| 243.4Cr | +26.42% | +32.30% | +14.78% | +13.31% | -5.01x | ||
| 566.51Cr | +26.50% | +29.43% | +18.99% | +15.45% | -0.64x | ||
| 31Cr | -245.59% | -232.51% | - | -50.20% | -0.8x | ||
| 188.71Cr | +13.23% | +13.30% | +12.68% | +8.89% | -5.76x | ||
| 124.33Cr | -43.11% | -21.54% | -86.15% | -1.86% | 1.96x | ||
| 29Cr | -181.75% | -144.69% | -51.94% | -32.60% | 2.5x | ||
| 5.06Cr | -205.30% | -166.94% | -58.43% | - | 2.98x | ||
| 83Cr | +33.96% | +40.71% | +293.15% | +20.80% | 2.73x | ||
| 183.02Cr | +11.35% | +9.34% | +8.74% | +6.91% | -5.06x | ||
| 16Cr | -12.22% | -37.48% | -3.46% | -2.93% | 11.91x | ||
| 29Cr | -180.51% | -170.79% | -818.43% | -50.27% | -0.33x | ||
| 75.3L | -6,988.63% | -6,589.71% | -321.32% | -57.23% | 0.02x | ||
| Average | 270.21Cr | -453.74% | -424.69% | -60.87% | -7.12% | -0.03x | |
| Weighted average by Cap. | 721.47Cr | -99.90% | -88.65% | -4.26% | +6.46% | -1.08x |
- Stock Market
- Equities
- PCVX Stock
- Sector Vaxcyte, Inc.
- Financial comparisons
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition